DIM
RCUS icon

DC Investments Management’s Arcus Biosciences RCUS Stock Holding History

DC Investments Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-19,617
Closed -$303K – 379
2018
Q1 		$303K Buy
+19,617
New +$327K 0.2% 176

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DC Investments Management's RCUS Position: Q2 2018 in Review

DC Investments Management sold out of Arcus Biosciences (RCUS) in Q2 2018, closing a stake of 19,617 shares — an estimated $303K sold.

DC Investments Management first reported a position in RCUS in Q1 2018 and held it in 1 quarter. The position peaked at $303K in Q1 2018. 64 funds tracked by Wall St. Rank hold RCUS as of Q2 2018.

  • DC Investments Management reported no remaining Arcus Biosciences position as of Q2 2018 after selling out during the quarter.
  • DC Investments Management sold 19,617 Arcus Biosciences shares in Q2 2018, an estimated $303K.
  • DC Investments Management first reported a position in Arcus Biosciences in Q1 2018 and held it in 1 quarter.
  • DC Investments Management's Arcus Biosciences position peaked at $303K in Q1 2018.
  • 64 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2018.

Based on DC Investments Management's 13F filing for Q2 2018, filed 3 Aug 2018.